For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240606:nRSF4536Ra&default-theme=true
RNS Number : 4536R Intl. Biotechnology Trust PLC 06 June 2024
INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")
Latest Factsheet and Blog
IBT's factsheet for the month ended 30 April 2024 is now available directly
via its web page. Please click here
(https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/)
, then 'latest factsheet'.
IBT recently celebrated its 30-year anniversary, having launched as a
pioneering investment trust dedicated to the nascent opportunity in biotech
back in 1994. In the latest blog post, Marking IBT's 30-year anniversary with
a look at the transformation of cancer therapy, Fund Managers Ailsa Craig and
Marek Poszepczynski explore the key developments in cancer treatment during
this time and the outlook for future breakthroughs, which are collectively
profoundly changing the prospects for many patients.
The blog can be read here:
https://www.schroders.com/en-gb/uk/individual/content/marking-ibt-s-30-year-anniversary-with-a-look-at-the-transformation-of-cancer-therapy/
(https://www.schroders.com/en-gb/uk/individual/content/marking-ibt-s-30-year-anniversary-with-a-look-at-the-transformation-of-cancer-therapy/)
To sign up for IBT updates by email, please click here
(https://www.schroders.com/en-gb/uk/individual/never-miss-an-update/) .
ENDS
Enquiries:
Schroder Investment Management Limited
Augustine Chipungu (Press) 020 7658 6000
Kirsty Preston
Kerry Higgins (Company Secretary) 020 7658 6000
Kaso Legg Communications (Financial PR)
Charles Gorman IBT@kl-communications.com (mailto:IBT@kl-communications.com)
Henry Taylor
Effie Aye Maung Hider
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFQLFBZQLXBBD